Difference between revisions of "Antithymocyte globulin, rabbit ATG (Grafalon)"
m |
Warner-admin (talk | contribs) m (Text replacement - "[http://online.lexi.com/ Lexicomp]" to "[https://online.lexi.com/lco/action/login UpToDate Lexidrug]") |
||
(23 intermediate revisions by 4 users not shown) | |||
Line 1: | Line 1: | ||
− | '' | + | ''This formulation of ATG is not FDA-approved in the United States, but is commonly used in Europe, the Middle East, and Asia.'' |
==General information== | ==General information== | ||
− | Class/mechanism: Contains antibodies against T-cell markers including CD2, CD3, CD4, CD8, CD11a, CD18, CD25, CD44, CD45, Beta-2 microglobulin, HLA Class I heavy chains, and HLA-DR. Exact mechanism not understood, but may involve removing T-cells from circulation and modifying T-cell activation, migration, proliferation, and cytotoxic effects. | + | Class/mechanism: Contains antibodies against T-cell markers including CD2, CD3, CD4, CD8, CD11a, CD18, CD25, CD44, CD45, Beta-2 microglobulin, HLA Class I heavy chains, and HLA-DR. Exact mechanism not understood, but may involve removing T-cells from circulation and modifying T-cell activation, migration, proliferation, and cytotoxic effects.<ref name="insert">[https://www.hpra.ie/img/uploaded/swedocuments/LicenseSPC_PA1015-001-001_27042016134023.pdf Antithymocyte globulin, rabbit ATG (Grafalon) package insert]</ref>><ref>[[File:Antithymocyteglobulinrabbitgrafalon.pdf | Antithymocyte globulin, rabbit ATG (Grafalon) package insert (locally hosted backup)]]</ref><ref>Finke J, Bethge WA, Schmoor C, Ottinger HD, Stelljes M, Zander AR, Volin L, Ruutu T, Heim DA, Schwerdtfeger R, Kolbe K, Mayer J, Maertens JA, Linkesch W, Holler E, Koza V, Bornhäuser M, Einsele H, Kolb HJ, Bertz H, Egger M, Grishina O, Socié G; ATG-Fresenius Trial Group. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol. 2009 Sep;10(9):855-64. Epub 2009 Aug 18. [https://doi.org/10.1016/S1470-2045(09)70225-6 link to original article] [https://pubmed.ncbi.nlm.nih.gov/19695955/ PubMed]</ref><ref>Kröger N, Solano C, Wolschke C, Bandini G, Patriarca F, Pini M, Nagler A, Selleri C, Risitano A, Messina G, Bethge W, Pérez de Oteiza J, Duarte R, Carella AM, Cimminiello M, Guidi S, Finke J, Mordini N, Ferra C, Sierra J, Russo D, Petrini M, Milone G, Benedetti F, Heinzelmann M, Pastore D, Jurado M, Terruzzi E, Narni F, Völp A, Ayuk F, Ruutu T, Bonifazi F. Antilymphocyte Globulin for Prevention of Chronic Graft-versus-Host Disease. N Engl J Med. 2016 Jan 7;374(1):43-53. [https://doi.org/10.1056/NEJMoa1506002 link to original article] [https://pubmed.ncbi.nlm.nih.gov/26735993/ PubMed]</ref> |
<br>Route: IV | <br>Route: IV | ||
<br>Extravasation: no information | <br>Extravasation: no information | ||
− | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. | + | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [https://online.lexi.com/lco/action/login UpToDate Lexidrug], [http://reference.medscape.com/drug/atgam-atg-equine-antithymocyte-globulin-equine-343190 Medscape], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> |
==Diseases for which it is used== | ==Diseases for which it is used== | ||
*[[Aplastic anemia]] | *[[Aplastic anemia]] | ||
+ | *[[Graft versus host disease]] | ||
*[[Myelodysplastic syndrome]] | *[[Myelodysplastic syndrome]] | ||
− | |||
+ | ==History of changes in EMA indication== | ||
+ | *1984-04-16: EURD | ||
==Also known as== | ==Also known as== | ||
− | + | *'''Generic names:''' anti-thymocyte globulin (rabbit), antithymocyte globulin (rabbit), lymphocyte immune globulin (rabbit) | |
+ | *'''Brand names:''' ATG-Fresenius, Grafalon | ||
==References== | ==References== | ||
<references/> | <references/> | ||
− | [[Category: | + | [[Category:Fractionated plasma products]] |
− | [[Category: | + | [[Category:Intravenous medications]] |
+ | [[Category:Antithymocyte globulin]] | ||
+ | |||
[[Category:Aplastic anemia medications]] | [[Category:Aplastic anemia medications]] | ||
[[Category:Myelodysplastic syndrome medications]] | [[Category:Myelodysplastic syndrome medications]] | ||
− | [[Category: | + | [[Category:Graft versus host disease medications]] |
+ | |||
+ | [[Category:EMA approved in 1984]] |
Revision as of 01:01, 27 June 2024
This formulation of ATG is not FDA-approved in the United States, but is commonly used in Europe, the Middle East, and Asia.
General information
Class/mechanism: Contains antibodies against T-cell markers including CD2, CD3, CD4, CD8, CD11a, CD18, CD25, CD44, CD45, Beta-2 microglobulin, HLA Class I heavy chains, and HLA-DR. Exact mechanism not understood, but may involve removing T-cells from circulation and modifying T-cell activation, migration, proliferation, and cytotoxic effects.[1]>[2][3][4]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, UpToDate Lexidrug, Medscape, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
History of changes in EMA indication
- 1984-04-16: EURD
Also known as
- Generic names: anti-thymocyte globulin (rabbit), antithymocyte globulin (rabbit), lymphocyte immune globulin (rabbit)
- Brand names: ATG-Fresenius, Grafalon
References
- ↑ 1.0 1.1 Antithymocyte globulin, rabbit ATG (Grafalon) package insert
- ↑ File:Antithymocyteglobulinrabbitgrafalon.pdf
- ↑ Finke J, Bethge WA, Schmoor C, Ottinger HD, Stelljes M, Zander AR, Volin L, Ruutu T, Heim DA, Schwerdtfeger R, Kolbe K, Mayer J, Maertens JA, Linkesch W, Holler E, Koza V, Bornhäuser M, Einsele H, Kolb HJ, Bertz H, Egger M, Grishina O, Socié G; ATG-Fresenius Trial Group. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol. 2009 Sep;10(9):855-64. Epub 2009 Aug 18. link to original article PubMed
- ↑ Kröger N, Solano C, Wolschke C, Bandini G, Patriarca F, Pini M, Nagler A, Selleri C, Risitano A, Messina G, Bethge W, Pérez de Oteiza J, Duarte R, Carella AM, Cimminiello M, Guidi S, Finke J, Mordini N, Ferra C, Sierra J, Russo D, Petrini M, Milone G, Benedetti F, Heinzelmann M, Pastore D, Jurado M, Terruzzi E, Narni F, Völp A, Ayuk F, Ruutu T, Bonifazi F. Antilymphocyte Globulin for Prevention of Chronic Graft-versus-Host Disease. N Engl J Med. 2016 Jan 7;374(1):43-53. link to original article PubMed